Henry Schein (HSIC) Stock Price, News & Analysis

Company Overview

Henry Schein, Inc. (NASDAQ:HSIC) is a leading global distributor of healthcare products and services, serving practitioners in the dental, medical and animal health markets. The company’s comprehensive portfolio spans consumable products, equipment, technology solutions and value-added services designed to help healthcare professionals improve operational efficiency and patient outcomes. Henry Schein’s distribution network leverages advanced logistics capabilities and a proprietary digital platform to support timely delivery and responsive customer service.

The company offers an extensive range of dental supplies, including restorative materials, imaging systems and dental laboratory products, alongside medical supplies such as exam gloves, surgical instruments and diagnostic test kits. In the animal health segment, Henry Schein provides vaccines, pharmaceuticals, imaging equipment and nutritional products tailored to veterinarians and their patients. Complementing its product offerings, the company delivers practice management software, clinical education and consulting services that enable practitioners to streamline workflows, optimize inventory and enhance clinical decision-making.

Founded in 1932 by Henry Schein, the firm has grown through strategic acquisitions and continuous innovation to maintain a broad and diverse catalog of healthcare solutions. Over the decades, the company has expanded its footprint beyond the United States to establish a presence in more than 30 countries, supported by regional warehouses and a dedicated sales force. This global reach allows Henry Schein to address the unique needs of practitioners in both mature and emerging markets while benefiting from economies of scale in procurement and distribution.

Under the leadership of Stanley M. Bergman, who serves as Chairman and Chief Executive Officer, Henry Schein has reinforced its commitment to ethical business practices and community engagement. The company’s executive team includes seasoned professionals with deep expertise in healthcare, technology and supply chain management, positioning Henry Schein to adapt to evolving industry trends and regulatory environments. Through ongoing investments in digital transformation and service innovation, Henry Schein aims to deliver long-term value to customers, partners and stakeholders worldwide.

Key Stats

• Today's Range: $73.13 to $74.30
• 50-Day Range: $66.24 to $74.67
• 52-Week Range: $60.56 to $82.49
• Volume: 1.45 million shs
• Average Volume: 1.73 million shs
• Market Capitalization: $8.94 billion
• P/E Ratio: 22.94
• Dividend Yield: N/A
• Price Target: $79.70
• Consensus Rating: Moderate Buy

Henry Schein Stock Analysis - MarketRank™

Henry Schein scored higher than 66% of companies evaluated by MarketBeat, and ranked 356th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Henry Schein has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Henry Schein has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 5.91%

Earnings Growth

Earnings for Henry Schein are expected to grow by 5.91% in the coming year, from $4.74 to $5.02 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Henry Schein is 22.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.84.

Price to Earnings Ratio vs. Sector

The P/E ratio of Henry Schein is 22.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.13.

Price to Earnings Growth Ratio

Henry Schein has a PEG Ratio of 2.40. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Henry Schein has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.90% of the float of Henry Schein has been sold short.

Short Interest Ratio / Days to Cover

Henry Schein has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Henry Schein has recently decreased by 9.61%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Henry Schein does not currently pay a dividend.

Dividend Growth

Henry Schein does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.4 / 5
• Environmental Score: -1.42

Percentage of Shares Shorted

6.90% of the float of Henry Schein has been sold short.

Short Interest Ratio / Days to Cover

Henry Schein has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Henry Schein has recently decreased by 9.61%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.87

News Sentiment

Henry Schein has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Henry Schein this week, compared to 12 articles on an average week.

MarketBeat Follows

Only 1 people have added Henry Schein to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Henry Schein insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.08% of the stock of Henry Schein is held by insiders.

Percentage Held by Institutions

96.62% of the stock of Henry Schein is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HSIC Stock Analysis - Frequently Asked Questions

How have HSIC shares performed this year?

Henry Schein's stock was trading at $69.20 at the beginning of 2025. Since then, HSIC shares have increased by 6.1% and is now trading at $73.42.

How were Henry Schein's earnings last quarter?

Henry Schein, Inc. (NASDAQ:HSIC) issued its earnings results on Monday, May, 5th. The company reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.11 by $0.04. Henry Schein's revenue for the quarter was down .1% compared to the same quarter last year.
Read the conference call transcript.

When did Henry Schein's stock split?

Shares of Henry Schein split on the morning of Friday, September 15th 2017.The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were distributed to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Does Henry Schein have any subsidiaries?

Henry Schein subsidiaries include Prism Medical Products LLC, Elite Computer Italia, Southern Anesthesia & Surgical, Marrodent, Dental Cremer, RxWorks, Dental Trey, and others.

Who are Henry Schein's major shareholders?

Henry Schein's top institutional investors include Swedbank AB (0.95%), Wealth Enhancement Advisory Services LLC (0.05%), Baker Ellis Asset Management LLC (0.04%) and Assenagon Asset Management S.A. (0.04%). Insiders that own company stock include James P Breslawski, Stanley M Bergman, Michael S Ettinger, Lorelei Mcglynn, Mark E Mlotek, David B Brous Jr, Bradford C Connett, Philip A Laskawy and Kurt P Kuehn.
View institutional ownership trends.

How do I buy shares of Henry Schein?

Shares of HSIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Henry Schein own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Henry Schein investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR), AU Optronics (AUOTY) and The RMR Group (RMR).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Health Care Distributors
• Current Symbol: NASDAQ:HSIC
• CIK: 1000228
• Web: www.henryschein.com
• Phone: (631) 843-5500
• Fax: 631-843-5541
• Employees: 25,000
• Year Founded: 1932

Price Target and Rating

• Average Price Target for Henry Schein: $79.70
• High Price Target: $86.00
• Low Price Target: $75.00
• Potential Upside/Downside: +8.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.20
• Trailing P/E Ratio: 22.94
• Forward P/E Ratio: 15.49
• P/E Growth: 2.4
• Net Income: $390 million
• Net Margins: 3.21%
• Pretax Margin: 4.19%
• Return on Equity: 14.87%
• Return on Assets: 5.82%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 1.38
• Quick Ratio: 0.75

Sales & Book Value

• Annual Sales: $12.67 billion
• Price / Sales: 0.71
• Cash Flow: $7.22 per share
• Price / Cash Flow: 10.17
• Book Value: $32.33 per share
• Price / Book: 2.27

Miscellaneous

• Outstanding Shares: 121,720,000
• Free Float: 120,405,000
• Market Cap: $8.94 billion
• Optionable: Optionable
• Beta: 0.87